Common questions about our model, how we work with companies, and what makes us different.

Learn More

From Pre-IND to NDA and everything in between, RRD has a proven track record of successful client engagements.

Learn More

RRD’s latest news stories, press releases, and other important announcements.

Read More

Executive Team

Charles (Chuck) Finn, PhD, Chief Executive Officer, Co-Founder

Dr. Finn is Chief Executive Officer at RRD International, LLC. Dr. Finn is responsible for the management of RRD’s core product development teams. Dr. Finn has more than 20 years of experience in the research, development, and government regulation of biological and pharmaceutical products covering a wide range of product types and therapeutic indications. Dr. Finn began his career as a Staff Fellow at FDA, Center for Biologics Evaluation and Research. He then entered industry, where he has held senior positions of increasing responsibility in regulatory affairs and product development. Dr. Finn worked for several companies prior to co-founding RRD, including Lederle-Praxis Biologicals, Miles Pharmaceuticals, Genetics Institute, BRI International, Quintiles, and Prestwick Clinical. Dr. Finn has extensive experience in establishing and managing drug development project teams. Dr. Finn received a PhD in Biology from Georgetown University and a BS in Zoology from the University of Maryland.

Frank Hurley, PhD, Chief Scientific Officer, Co-Founder

Dr. Hurley is Chief Scientific Officer at RRD International, LLC. Dr. Hurley has more than 30 years of experience in assisting companies with their regulatory, research, and product development strategies. His expertise includes clinical trial design and analysis, review of preclinical and clinical information, preparation of regulatory documents, and presentations to government regulatory agencies. Dr. Hurley is a recognized published educator and authority on research strategy and study design for pharmaceuticals, biologics, and medical devices. Dr. Hurley co-founded BRI International, Inc. in 1971 and guided its growth as both Chairman and Chief Scientific Officer until he merged BRI with Quintiles Transnational, Inc. in 1996. Dr. Hurley served as Chief Scientific Officer of Quintiles until 2001. Dr. Hurley received a PhD in Biostatistics from Johns Hopkins University and a BS in Mathematics and Pre-Medical Sciences from Georgetown University.

J. Scott Tarrant, President

Mr. Tarrant has over 20 years of technical sales, marketing and business development experience with companies ranging from early stage start-ups to large publically traded entities. As Partner and Co-Founder of Catenate, LLC he has worked closely with a number of early stage life science companies developing and supporting their corporate and business strategies. Mr. Tarrant served previously as EVP Global Sales and Marketing for UK based Xceleron Ltd, joining the company in 2004, and leading the formation of Xceleron’s US subsidiary in Maryland. Mr. Tarrant has also held executive and sales management positions at Gene Logic, TherImmune Research Corporation and Nalco Chemical Company. Mr. Tarrant is a former combat engineer officer in the United States Army. He received his B.S. in Biology from SUNY College of Environmental Science and Syracuse University and is a 2008 graduate of the International Executive Program in General Management at INSEAD, Fontainebleau, France and Singapore.

Curt Scribner, MD, MBA, Senior Vice President of Medical and Regulatory Affairs

Dr. Scribner is Senior Vice President of Medical and Regulatory Affairs at RRD International, LLC. Dr. Scribner is a board certified physician in internal medicine and has direct experience running large clinical programs. He joined RRD from Intarcia Therapeutics, where he was the Vice President of Regulatory and Quality Affairs and Chief Regulatory Officer. Previously, Dr. Scribner was Chief Regulatory Consultant for Quintiles Consulting, where he developed and wrote numerous NDA, BLA, IND, IDE, 510(k), PMA, and MAA applications. Prior to Quintiles Consulting, Dr. Scribner spent 10 years at FDA, where he held a variety of positions and was involved in reviewing products regulated by the Center for Biologics. Dr. Scribner holds an MD from the University of Colorado College of Medicine, an MBA from the University of Maryland College of Business and Management, and a BA in biology from Grinnell College.

Robert L Smith, Jr., CPA, Senior Vice President of Finance and Administration

Mr. Smith is Senior Vice President, Finance and Administration, at RRD International, LLC. Mr. Smith is a CPA and has extensive experience in the areas of financial reporting, accounting systems, auditing, budgeting and analysis, cost control, and financial management. Previous employers have consisted predominately of small (including start-up) to mid-size firms providing products and services to the biotechnology, pharmaceutical, and medical research industries. He is recognized for his ability to successfully organize, plan, and coordinate staff efforts in start-up ventures, finance system conversions, systems integrations, and mergers/acquisitions. Mr. Smith was previously Vice President of Finance and Administration for East West Resources Corporation, a private investment management firm. Prior to that he was Divisional Vice President of Finance at Quintiles Transnational Corp. Mr. Smith began his career as a Senior Staff Accountant at Arthur Andersen & Company in Baltimore, MD.

Patrick (Pat) Frenchick, PhD, MBA, Sr. Vice President of Scientific and Technical Operations

Dr. Frenchick has over 25 years of experience in the development of new therapeutic technologies, from discovery through initiation of clinical trials. Prior to joining RRD, he was Vice President for Clinical Operations at CytImmune Sciences, and before that Vice President of Development at Combinature BioPharma. He has worked in senior positions in research and development, the acquisition of technologies, strategic planning, and portfolio management in the US and in Europe. He has held the following academic positions: Adjunct Assistant Professor of Microbiology at the University of Saskatchewan, Research Faculty member at the Veterinary Infectious Disease Organization, and Postdoctoral Fellow in Virology at Baylor College of Medicine. Dr. Frenchick received a PhD in Immunology from the University of Minnesota and an MBA from Queen's University (Kingston, ON, Canada). He is also a US Patent Agent.